Tsugiko Oze

1.1k total citations
24 papers, 367 citations indexed

About

Tsugiko Oze is a scholar working on Hepatology, Epidemiology and Immunology. According to data from OpenAlex, Tsugiko Oze has authored 24 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 16 papers in Epidemiology and 5 papers in Immunology. Recurrent topics in Tsugiko Oze's work include Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (11 papers). Tsugiko Oze is often cited by papers focused on Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (11 papers). Tsugiko Oze collaborates with scholars based in Japan, United States and Germany. Tsugiko Oze's co-authors include Naoki Hiramatsu, Tetsuo Takehara, Tatsuya Kanto, Takayuki Yakushijin, Norio Hayashi, Tomohide Tatsumi, Akinori Kasahara, Masanori Miyazaki, Naoki Harada and Takuya Miyagi and has published in prestigious journals such as Journal of Hepatology, Journal of Medical Virology and Cancer Immunology Immunotherapy.

In The Last Decade

Tsugiko Oze

22 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tsugiko Oze Japan 12 297 262 68 31 22 24 367
Zehui Yan China 11 237 0.8× 253 1.0× 64 0.9× 22 0.7× 4 0.2× 18 354
David Goldstein United States 8 253 0.9× 251 1.0× 24 0.4× 11 0.4× 3 0.1× 12 368
D. Petruzzellis Italy 6 420 1.4× 351 1.3× 33 0.5× 17 0.5× 14 439
M. Maynard-Muet France 9 220 0.7× 214 0.8× 33 0.5× 29 0.9× 15 323
Nancy Fryzek United States 5 253 0.9× 238 0.9× 63 0.9× 10 0.3× 1 0.0× 7 316
Raffaella Francesconi Italy 11 328 1.1× 268 1.0× 26 0.4× 17 0.5× 13 398
Ildikó Földi Hungary 8 55 0.2× 183 0.7× 91 1.3× 29 0.9× 2 0.1× 13 346
Kornelija Suveizdytė United Kingdom 6 156 0.5× 234 0.9× 202 3.0× 106 3.4× 4 0.2× 6 474
Tomoo Kobayashi Japan 8 173 0.6× 176 0.7× 46 0.7× 10 0.3× 1 0.0× 23 253
Yutaka Mano Japan 9 155 0.5× 134 0.5× 37 0.5× 18 0.6× 23 260

Countries citing papers authored by Tsugiko Oze

Since Specialization
Citations

This map shows the geographic impact of Tsugiko Oze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsugiko Oze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsugiko Oze more than expected).

Fields of papers citing papers by Tsugiko Oze

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsugiko Oze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsugiko Oze. The network helps show where Tsugiko Oze may publish in the future.

Co-authorship network of co-authors of Tsugiko Oze

This figure shows the co-authorship network connecting the top 25 collaborators of Tsugiko Oze. A scholar is included among the top collaborators of Tsugiko Oze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsugiko Oze. Tsugiko Oze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oze, Tsugiko, Naoki Hiramatsu, & Tetsuo Takehara. (2015). [Pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C].. PubMed. 73(2). 249–58. 2 indexed citations
2.
3.
4.
Oze, Tsugiko, Naoki Hiramatsu, Takayuki Yakushijin, et al.. (2014). The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. Journal of Gastroenterology. 50(3). 313–322. 3 indexed citations
5.
Hiramatsu, Naoki, Tsugiko Oze, & Tetsuo Takehara. (2014). Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon‐based antiviral therapy. Hepatology Research. 45(2). 152–161. 57 indexed citations
6.
Morishita, Naoki, Naoki Hiramatsu, Tsugiko Oze, et al.. (2013). Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. Journal of Gastroenterology. 49(7). 1175–1182. 51 indexed citations
7.
Oze, Tsugiko, Naoki Hiramatsu, Eiji Mita, et al.. (2013). A multicenter survey of re‐treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatology Research. 43(1). 35–43. 7 indexed citations
8.
Yamada, Ryoko, Naoki Hiramatsu, Tsugiko Oze, et al.. (2013). Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients. Journal of Medical Virology. 86(2). 241–247. 13 indexed citations
9.
Kohga, Keisuke, Tomohide Tatsumi, Hinako Tsunematsu, et al.. (2012). Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunology Immunotherapy. 61(9). 1425–1432. 17 indexed citations
10.
Kanto, Tatsuya, Shoko Kuroda, Sachiyo Yoshio, et al.. (2012). Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. Journal of Gastroenterology. 48(5). 660–670. 40 indexed citations
11.
Song, Cheng, Noriyuki Hiramatsu, Tsugiko Oze, et al.. (2011). 333 THE USEFULLNESS OF VS/PLT: A NEW MARKER OF LIVER FIBROSIS. Journal of Hepatology. 54. S133–S134. 1 indexed citations
12.
Kanto, Tatsuya, Michiyo Inoue, Tsugiko Oze, et al.. (2011). Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. Journal of Gastroenterology. 47(2). 169–178. 9 indexed citations
13.
Inoue, Yuko, Naoki Hiramatsu, Tsugiko Oze, et al.. (2011). Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. Journal of Medical Virology. 83(3). 419–427. 4 indexed citations
14.
Hayashi, Norio, Naoki Hiramatsu, & Tsugiko Oze. (2010). Interferon therapy and new antiviral drugs for chronic hepatitis C.. 53(4). 229–235.
15.
Hayashi, Norio, Tsugiko Oze, & Naoki Hiramatsu. (2008). [Development of antiviral therapy for patients with chronic hepatitis C].. PubMed. 105(2). 175–85.
16.
Hiramatsu, Naoki, Takayuki Yakushijin, Tsugiko Oze, et al.. (2008). A New Prognostic System for Hepatocellular Carcinoma Including Recurrent Cases. Journal of Clinical Gastroenterology. 42(3). 317–322. 15 indexed citations
17.
Hiramatsu, Naoki, Tsugiko Oze, Tetsuo Takehara, et al.. (2007). Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatology Research. 38(1). 52–59. 20 indexed citations
18.
Itose, Ichiyo, Tatsuya Kanto, Michiyo Inoue, et al.. (2007). Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon‐α and ribavirin therapy for chronic hepatitis C patients. Journal of Medical Virology. 79(5). 511–521. 11 indexed citations
19.
Oze, Tsugiko, Naoki Hiramatsu, Natsuko Tsuda, et al.. (2006). Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Journal of Gastroenterology. 41(9). 862–872. 16 indexed citations
20.
Hiramatsu, Naoki, Tsugiko Oze, N. Tsuda, et al.. (2006). Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?. Hepatology Research. 35(3). 185–9. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zehui Yan Breakdown of academic impact, for papers by David Goldstein Breakdown of academic impact, for papers by D. Petruzzellis Breakdown of academic impact, for papers by M. Maynard-Muet Breakdown of academic impact, for papers by Nancy Fryzek Breakdown of academic impact, for papers by Raffaella Francesconi Breakdown of academic impact, for papers by Ildikó Földi Breakdown of academic impact, for papers by Kornelija Suveizdytė Breakdown of academic impact, for papers by Tomoo Kobayashi Breakdown of academic impact, for papers by Yutaka Mano
Rankless by CCL
2026